Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Codexis Inc

Healthcare US CDXS

2.605USD
0.04(1.76%)

Last update at 2026-06-08T20:15:00Z

Day Range

2.602.67
LowHigh

52 Week Range

0.963.87
LowHigh

Fundamentals

  • Previous Close 2.56
  • Market Cap219.00M
  • Volume551159
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-33.08400M
  • Revenue TTM70.39M
  • Revenue Per Share TTM0.81
  • Gross Profit TTM 8.74M
  • Diluted EPS TTM-0.5

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -43.92700M -65.24200M -76.17100M -33.31600M -21.09000M
Minority interest - - - - -
Net income -43.97400M -65.27600M -76.24000M -33.59200M -21.27900M
Selling general administrative 47.07M 55.15M 52.95M 52.17M 49.32M
Selling and marketing expenses - - 0.30M - -
Gross profit 55.95M 43.06M 57.33M 100.56M 82.55M
Reconciled depreciation 5.25M 4.95M 10.62M 10.25M 5.95M
Ebit -38.33200M -58.35400M -54.80100M -31.71400M -28.64400M
Ebitda -30.04000M -58.51900M -49.28300M -28.54700M -22.69700M
Depreciation and amortization 8.29M -0.16500M 5.52M 3.17M 5.95M
Non operating income net other - - - - 1.61M
Operating income -38.33200M -58.51900M -68.06900M -31.71400M -22.69700M
Other operating expenses 108.72M 117.86M 138.21M 170.30M 127.45M
Interest expense 4.81M 10.39M 12.27M 1.44M 7.55M
Tax provision 0.05M 0.03M 0.18M 0.28M 0.19M
Interest income 2.62M 3.67M 4.09M 1.44M 0.46M
Net interest income -2.18800M 3.67M 4.09M 1.44M 0.46M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.05M 0.03M 0.07M 0.28M 0.19M
Total revenue 70.39M 59.34M 70.14M 138.59M 104.75M
Total operating expenses 94.28M 101.58M 125.40M 132.27M 105.24M
Cost of revenue 14.44M 16.29M 12.81M 38.03M 22.21M
Total other income expense net -5.59500M -6.72300M -8.10200M -1.60200M 1.61M
Discontinued operations - - - - -
Net income from continuing ops -43.97400M -65.27600M -81.65200M -33.59200M -21.27900M
Net income applicable to common shares - - - -33.59200M -21.27900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 147.80M 149.01M 136.56M 250.39M 246.38M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.06M 4.63M 5.22M 5.49M 6.28M
Total liab 97.27M 82.08M 49.95M 105.60M 81.99M
Total stockholder equity 50.53M 66.93M 86.61M 144.80M 164.39M
Deferred long term liab - - - 0.02M 0.06M
Other current liab 13.81M 17.63M 15.98M 26.73M 23.70M
Common stock 0.00900M 0.00800M 0.00700M 0.00600M 0.00600M
Capital stock 0.00900M 0.00800M 0.00700M 0.00600M 0.00600M
Retained earnings -606.78000M -562.80600M -497.53000M -421.29000M -387.69800M
Other liab - - - 18.25M 5.06M
Good will 2.46M 2.46M 2.46M 3.24M 3.24M
Other assets - - - 1.87M 1.79M
Cash 50.79M 19.26M 65.64M 113.98M 116.80M
Cash and equivalents - - - - -
Total current liabilities 25.32M 23.65M 35.83M 49.07M 33.37M
Current deferred revenue 7.01M 0.35M 3.78M 13.73M 2.59M
Net debt 22.41M 40.63M -43.27100M -70.34600M -69.14300M
Short term debt 2.94M 2.83M 10.12M 5.36M 4.09M
Short long term debt - - - - -
Short long term debt total 73.21M 59.90M 22.36M 43.64M 47.65M
Other stockholder equity 657.29M 629.67M 584.14M 566.08M 552.08M
Property plant equipment - - - 61.88M 65.46M
Total current assets 96.82M 98.77M 93.47M 162.89M 161.89M
Long term investments 2.50M 2.80M 9.70M 20.51M 14.00M
Net tangible assets - - - 141.56M 161.15M
Short term investments 27.42M 54.19M - - 0.00000M
Net receivables 10.73M 18.88M 19.93M 40.87M 37.65M
Long term debt 40.10M 28.91M - - -
Inventory 1.82M 1.80M 2.69M 2.03M 1.16M
Accounts payable 1.55M 2.84M 5.95M 3.25M 3.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.00800M 0.05M 0.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - 0.00600M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -387.69800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.50M 2.08M 1.25M 1.87M 1.79M
Deferred long term asset charges - - - - -
Non current assets total 50.98M 50.24M 43.09M 87.50M 84.50M
Capital lease obligations 33.10M 30.99M 16.02M 43.64M 47.65M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 27.97M -56.98000M -5.92900M -13.57800M -7.63000M
Change to liabilities - - - 24.73M 1.57M
Total cashflows from investing activities 23.50M -56.98000M -4.85800M -13.57800M -21.42200M
Net borrowings 9.90M 29.52M 0.00000M - -
Total cash from financing activities 27.93M 60.52M 8.17M -0.57500M 3.77M
Change to operating activities - - - 0.94M 0.16M
Net income -43.97400M -65.27600M -76.24000M -33.59200M -21.27900M
Change in cash 32.05M -45.86800M -49.32900M -2.86900M -31.92200M
Begin period cash flow 20.83M 66.70M 116.03M 118.89M 150.82M
End period cash flow 52.88M 20.83M 66.70M 116.03M 118.89M
Total cash from operating activities -19.37600M -49.41000M -52.63800M 11.28M -14.26700M
Issuance of capital stock 17.27M 31.32M 8.65M 0.00000M 0.00000M
Depreciation 5.25M 4.95M 9.92M 10.25M 5.95M
Other cashflows from investing activities 0.00500M 0.09M -0.44000M - 0.04M
Dividends paid - - - - -
Change to inventory -0.01900M 0.89M -0.65600M -0.86900M -0.19600M
Change to account receivables 8.51M 1.25M 20.25M -3.22500M -15.57100M
Sale purchase of stock - - -0.40400M - 4.97M
Other cashflows from financing activities 27.93M -0.31800M -0.48500M -1.53000M 3.77M
Change to netincome - - - 13.05M 8.69M
Capital expenditures 4.47M 4.30M 4.42M 8.31M 13.83M
Change receivables - - - - -9.15600M
Cash flows other operating - - - - -1.36100M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -31.92200M
Change in working capital 6.42M -12.01600M -18.21700M 21.57M -7.62400M
Stock based compensation 9.62M 13.09M 9.97M 14.53M 11.59M
Other non cash items 3.31M 9.85M 21.93M -1.47800M -0.01900M
Free cash flow -23.84700M -53.71500M -57.05600M 2.98M -28.09500M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CDXS
Codexis Inc		 0.04 1.76% 2.60 - 149.25 3.11 4.71 3.31 -10.672
NVO
Novo Nordisk A/S		 -1.94 4.52% 41.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.11 4.87% 41.25 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.87 0.87% 442.96 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -24.11 3.79% 611.34 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Codexis Inc

200 Penobscot Drive, Redwood City, CA, United States, 94063

Key Executives

Name Title Year Born
Dr. Stephen George Dilly MBBS, Ph.D. Pres, CEO & Director 1960
Mr. Ross Taylor Jr., M.B.A. Sr. VP & CFO 1963
Mr. John J. Nicols Director & Strategic Advisor 1964
Mr. Kevin Norrett M.B.A., M.S. Chief Operating Officer 1973
Ms. Margaret Fitzgerald J.D. Chief Legal and Compliance Officer, Gen. Counsel & Sec. NA
Ms. Asli Aras Ph.D. VP & Head of Corp. Devel. NA
Ms. Karen Frechou-Armijo Sr. VP & Head of HR NA
Mr. Rob Wilson Ph.D. Sr. VP & GM of Performance Enzymes NA
Dr. Karl A. Schoene Ph.D. Sr. VP of Devel. & Operations NA
Dr. Stefan Lutz Ph.D. Sr. VP of Research NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.